CLINICIANS

ACTIfit Clinical Studies

The ACTIfit meniscal scaffold has been implanted in over 4000 patients in 30 countries worldwide and has now been published in 25 peer-reviewed clinical journals, including a pivotal paper reviewing 155 patients after five years that was recently published in the American Journal of Sports Medicine. ACTIfit is a biodegradable polymer designed to preserve the knee joint and promote new tissue growth in damaged areas of the meniscus that are irreparable.

The Actifit 5-year results have recently been accepted for publication in the American Journal of Sports Medicine.

  • 5 years, 155 patients
  • 6 centers in Ghent, Belgium; Versailles, France; Warwick, UK; Barcelona, Spain; Bologna, Italy; Varese, Italy
Clinical Results

ACTIfit’s five-year clinical results have recently been published in the American Journal of Sports Medicine, published in over 25 peer-reviewed clinical papers, and cited in over 100 journal articles. Key clinicians from across the world have presented ACTIfit in congresses and conferences over the last 10 years.

Polyurethane Meniscal Scaffold for the Treatment of Partial Meniscal Deficiency: 5 Year Follow-up Outcomes
A European Multicentric Study

Cecile Toanen, MD, Aad Dhollander, MD, PT, PhD, Paolo Bulgheroni, MD, Giuseppe Filardo, MD, PhD, Stefano Zaffagnini, MD, PhD, Tim Spalding, MD, Joan Carles Monllau, MD, PhD, Pablo Gelber, MD, Rene Verdonk, MD, PhD, Philippe Beaufils, MD, PhD, Nicolas Pujol, MD, PhD, and Peter Verdonk, Md, PhD.

Investigation performed at the Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France.

Click here to see the AJSM publication of ACTIfit's 5-year resultsClick here to see the other key ACTIfit publications

The patient must have an intact meniscal rim, with anterior and posterior horns present, to enable attachment of ACTIfit. The procedure is performed arthroscopically, usually with spinal or general anesthesia. If the initial meniscus lesion cannot be sutured (repaired), then damaged tissue is removed in much the same way as in a partial meniscectomy and cut back to an area with good blood supply.

Click here to see ACTIfit IFU
Recent Publications

Medial Meniscus Scaffold Implantation in Combination with Concentrated Bone Marrow Aspirate Injection: Minimum 3-Year Follow-up.
J Knee Surg. 2020 Feb 10. doi: 10.1055/s-0040-1701452. [Epub ahead of print]

Polyurethane scaffold implants for partial meniscus lesions: delayed intervention leads to an inferior outcome.
Knee Surg Sports Traumatol Arthrosc.
2019 Oct 25. doi: 10.1007/s00167-019-05760-4. [Epub ahead of print]
Condello V, Dei Giudici L, Perdisa F, Screpis DU, Guerriero M, Filardo G, Zorzi C.

Meniscus Scaffolds for Partial Meniscus Defects.
de Caro F, Perdisa F, Dhollander A, Verdonk R, Verdonk P. Clinical Sports Med

If you are interested in more Orteq clinical information, please contact us.
E-mail:

Further Information

For further information on the Clinical Studies:

Professor Emeritus René Verdonk
Chief of the Orthopedic and Trauma Department at the University Hospital, Gent, Belgium.

Or

Dr Philippe Beaufils
Centre Hospitalier de Versailles, Versailles, France
or

Actifit is available at the following world renowned clinics:

Prof Peter Verdonk, Orthoca Orthopedic Center, Antwerp, Belgium.

Mr Tim Spalding, Fortius Clinic, London, UK and Warwickshire Nuffield Hospital, Warwick, UK


Emmanuel Pappacostas MD, Aspetar Clinic, Qatar

Nicolas Pujol MD PhD, Orthopedic Department, Centre Hospitalier de Versailles, Le Chesnay, France